Ann: Appendix 4E & Annual Report to shareholders, page-30

There's always more than one perspective. Dr Roger Aston is a guru in this space. At #15 on the list, I'm supremely confident he's done a mountain of DD prior to tipping in for $1.5M of shares! I'd imagine he's quite well versed in updates in regards to progress. I take loads of comfort in discovering within the annual report that a fellow of his calibre also has his hard earned right next to mine..albeit a different quantity! Like many of us, he's being patient and hoping for a Disallowed!

Dr Aston has more than 20 years experience in the pharmaceutical and biotech industries. He was the founding Chief Executive Officer of Mayne Pharma Group Limited, after leading HalcyGen’s acquisition of Mayne Limited in 2009. He has extensive experience with FDA and EU product registration, clinical trials, global licensing, private placement fundraising and prospectus preparation. Dr Aston has held numerous other board positions in the sector including with Clinuvel Limited, HalyGen Limited and Ascent Pharma Health Limited, recently acquired by Watson.

Good luck to all and your own perspectives of the Annual report. My view is total bluesky!!